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Sarcopenic obesity and myosteatosis are associated
with higher mortality in patients with cirrhosis
Aldo J. Montano-Loza1*, Paul Angulo2, Judith Meza-Junco3, Carla M. M. Prado4, Michael B. Sawyer3, Crystal Beaumont3,
Nina Esfandiari3, Mang Ma1 & Vickie E. Baracos3
1Division of Gastroenterology & Liver Unit, University of Alberta Hospital, Edmonton, Alberta, Canada; 2Division of Digestive Diseases & Nutrition, University of Kentucky
Medical Center, Lexington, KY, USA; 3Department of Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada; 4Department of Agricultural, Food and Nutritional
Sciences, Edmonton, Alberta, Canada
Abstract
Background and aims Obesity is frequently associated with cirrhosis, and cirrhotic patients may develop simultaneous loss
of skeletal muscle and gain of adipose tissue, culminating in the condition of sarcopenic obesity. Additionally, muscle depletion
is characterized by both a reduction in muscle size and increased proportion of muscular fat, termed myosteatosis. In this
study, we aimed to establish the frequency and clinical significance of sarcopenia, sarcopenic obesity and myosteatosis in cir-
rhotic patients.
Methods We analysed 678 patients with cirrhosis. Sarcopenia, sarcopenic obesity and myosteatosis were analysed by CT
scan using the third lumbar vertebrae skeletal muscle and attenuation indexes, using previously validated gender-and body
mass index-specific cutoffs.
Results Patients were predominately men (n = 457, 67%), and cirrhosis aetiology was hepatitis C virus in 269 patients (40%),
alcohol in 153 (23%), non-alcoholic steatohepatitis/cryptogenic in 96 (14%), autoimmune liver disease in 55 (8%), hepatitis B
virus in 43 (6%), and others in 5 patients (1%). Sarcopenia was present in 292 (43%), 135 had sarcopenic obesity (20%) and 353
had myosteatosis (52%). Patients with sarcopenia (22 ± 3 vs. 95 ± 22months, P< 0.001), sarcopenic obesity (22 ± 3 vs. 95
± 22months, P< 0.001), and myosteatosis (28 ± 5 vs. 95 ± 22months, P< 0.001) had worse median survival than patients with-
out muscular abnormalities. By multivariate Cox regression analysis, both sarcopenia [hazard ratio (HR) 2.00, 95% confidence
interval (CI) 1.44–2.77, P< 0.001], and myosteatosis (HR 1.42, 95% CI 1.02–1.07, P = 0.04) were associated with mortality.
Conclusions Sarcopenia, sarcopenic obesity and myosteatosis are often present in patients with cirrhosis, and sarcopenia
and myosteatosis are independently associated with a higher long-term mortality in cirrhosis.
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Introduction
Overweight and obesity are endemic in Western countries
comprising up to 35% of the total population.1,2 Over-
weight and obesity have been associated with development
of chronic liver disease, worsening of liver fibrosis and pro-
gression to cirrhosis,3,4 and the body mass index (BMI) has
been considered an independent risk factor for the devel-
opment of decompensation among cirrhotic patients of all
causes.5
Severe muscle depletion or sarcopenia is one of the most
common complications in cirrhosis,6–10 and despite its impor-
tant role in the prognosis of cirrhosis, it is frequently
overlooked as body composition assessments can be chal-
lenging in cirrhotic patients with fluid retention or who are
overweight or frankly obese.11,12
Muscularity assessment with cross-sectional imaging
studies has become an attractive index of nutritional status
evaluation in cirrhosis,13,14 and different methods have been
used for the estimation of the muscle mass from axial CT
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scans, such as the psoas muscle area, or the thickness of the
psoas muscle at different levels of lumbar spine (L3, L4) or at
the level of umbilicus,15–17 and the cross-sectional area of
muscle normalized for stature referred to as the L3 skeletal
muscle index (L3 SMI).18
The CT analysis is not biased by the fluid overload that
frequently presents in decompensated cirrhosis, and
sarcopenia reflects a chronic detriment in general physical
condition, rather than acute severity of the liver disease.19
Sarcopenia in cirrhosis is part of the frailty complex present
in these patients, characterized by a decreased reserve and
resistance to stressors and predisposition to poor out-
comes.20–23
Patients with cirrhosis may develop simultaneous loss of
skeletal muscle and gain of adipose tissue, culminating
in the condition of ‘sarcopenic obesity’.24,25 In addition,
muscle depletion is characterized by both a reduction in
muscle size and increased proportion of intermuscular and
intramuscular fat denominated ‘myosteatosis’. Myosteatosis
increases with age and adiposity26 and is associated
with metabolic abnormalities,27 decreased strength and
mobility.28
In this study, our goals were to establish the frequency and
factors associated with sarcopenia, sarcopenic obesity and
myosteatosis in a cohort of cirrhotic patients evaluated for
liver transplantation. In this fashion, we aimed to establish




Six hundred and seventy-eight adult patients with cirrhosis
who were evaluated for liver transplantation between
January 2000 and May 2013 at the University of Alberta
Hospital (Edmonton, AB, Canada) and had an abdominal CT
scan including the third lumbar (L3) vertebrae as part of their
pre-transplant evaluation were evaluated.
Clinical and laboratory assessments
Data recovered from medical charts included gender, age,
weight, height, cirrhosis aetiology and liver biochemistries,
serum albumin, serum creatinine, international normalized
ratio (INR), Child–Pugh and model for end stage liver disease
(MELD) scores. Clinical, laboratory and radiological data used
for the analysis, and to calculate MELD and Child–Pugh scores
were obtained within 1week from the CT used to quantify
muscle indices (time zero).
Sarcopenia, sarcopenic obesity and myosteatosis
evaluation
The CT scans used for analysis were carried out as part of
the liver transplant assessment. A transverse CT image from
L3 was assessed from each scan. Images were analysed
with SliceOmatic V4.3 software (Tomovision, Montreal, QB,
Canada), which enables specific tissue demarcation using pre-
viously reported Hounsfield unit (HU) thresholds.29 Skeletal
muscle is identified and quantified by HU thresholds of 29
to +150. Muscles in the L3 region encompass psoas, erector
spinae, quadratus lumborum, transversus abdominus, exter-
nal and internal obliques, and rectus abdominus. The follow-
ing HU thresholds were used for adipose tissues: 190 to
30 for subcutaneous and intermuscular adipose tissues30
and 150 to 50 for visceral adipose tissues.31 Using these
specific HU thresholds, measurements of the skeletal muscle
index are not influenced by the presence of ascites in patients
with cirrhosis. Cross-sectional areas (cm2) were automatically
computed by summing tissue pixels and multiplying by pixel
surface area. All CT images were analysed by two trained ob-
servers (C. B., and N. E.) who demonstrated an intra-observer
coefficient variation of 1.3%. Cross-sectional area of muscle
and adipose tissue was normalized for stature (cm2/m2) as
reported elsewhere,18 and this value is referred to as the
L3 SMI. Cutoffs for sarcopenia were based on a CT-based
study in patients with solid tumours using optimal stratifica-
tion, a statistical method similar to receiver operator curve
analysis, to solve specific threshold values for L3 SMI in
relation to an outcome (death) (L3 SMI: ≤41 cm2/m2 for
women and ≤53 cm2/m2 for men with BMI ≥25 and
≤43 cm2/m2 in patients with BMI <25).32 Muscle attenua-
tion indirectly measures fat infiltration in muscles. Mean
muscle attenuation in HU was reported for the entire mus-
cle area at the third lumbar vertebra. We also, used
previous cutoff values for muscle attenuation previously as-
sociated with mortality, specifically <41HU in patients with
a BMI up to 24.9, and <33 in those with a BMI ≥25.32
Finally, sarcopenic obesity was defined as those patients
with concurrent sarcopenia and overweight or obesity
(BMI> 25 kg/m2).
Statistical analyses
The Fisher’s exact probability was used to compare categori-
cal variables, and the unpaired t-test was used to compare
differences in means of continuous variables. Survival was
calculated using Kaplan–Meier method, and they were com-
pared using the Log Rank (Mantel–Cox) test. Patients were
followed from the date of the CT performed for muscle indi-
ces (time zero), until the date of death, liver transplantation
or last visit. As malignancy is strongly associated with muscle
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abnormalities,33 a survival sub-analysis excluding patients
with hepatocellular carcinoma (HCC) was performed.
Prognostic factors for mortality were analysed by Cox re-
gression univariate and multivariate analyses. Biochemical
parameters, such as serum bilirubin, creatinine, sodium and
albumin, were included in the regression analysis as dimen-
sional variables, whereas clinical variables, such as sarcopenia
and myosteatosis, were entered as categorical variables
(present or absent). Data are presented as the mean ±
standard error of the mean in tables and text.
Results
Clinical and biochemical features of patients with
sarcopenia, sarcopenic obesity and myosteatosis
Four hundred and fifty-seven patients were men (67%), and
cirrhosis aetiology was hepatitis C virus in 269 patients
(40%), alcohol in 153 (23%), non-alcoholic steatohepatitis
(NASH)/cryptogenic in 96 (14%), autoimmune liver disease
in 55 (8%), hepatitis B virus in 43 (6%) and others in 5 pa-
tients (1%), and 291 patients had concomitant HCC (43%).
Two hundred and ninety-two patients had sarcopenia
(43%), 135 patients had sarcopenic obesity (20%), 353 pa-
tients had myosteatosis (52%) and 176 patients had both,
sarcopenia and myosteatosis (26%). In Figure 1, we illustrate
the overlapping of sarcopenia, myosteatosis and obesity
using a Venn diagram. Figure 2(A and B) illustrates two cir-
rhotic patients with severe obesity (BMI >40 kg/m2). Abdo-
minal CT images in horizontal plane are images taken at
third lumbar vertebra, and the red colour indicates skeletal
muscles. CT at the left [Figure 2(A)] is from a male patient
with sarcopenic obesity, with BMI of 47 kg/m2 and L3 SMI
51 cm2/m2, and the CT at the right [Figure 2(B)] is from a fe-
male patient without sarcopenia, with BMI 42 kg/m2 and L3
SMI 49 cm2/m2.
Figure 2(C and D) illustrates two cirrhotic patients with
similar BMI (28 kg/m2). The patient at the left [Figure 2(C)]
had myosteatosis with low mean muscle attenuation
(21HU), whereas the patient at the right [Figure 2(D)] had
normal mean muscle attenuation (40HU).
Patients with sarcopenia were more frequently men
(P = 0.003), and less frequently overweight–obese
(P< 0.001), had lower weight (P< 0.001), BMI (P< 0.001),
L3 SMI (P< 0.001), and muscle attenuation (P< 0.001), had
higher height (P< 0.001), levels of serum creatinine
(P = 0.001), INR (P = 0.006), MELD (P = 0.006) and Child–Pugh
scores (P< 0.001) compared with patients with no muscular
abnormalities (Table 1).
Patients with sarcopenic obesity were older (P = 0.02), and
more frequently men (P = 0.001), had higher weight
(P< 0.001), and height (P< 0.001), and lower L3 SMI
(P< 0.001), and muscle attenuation (P< 0.001), higher levels
of serum creatinine (P< 0.001), and bilirubin (P = 0.02), MELD
(P = 0.009) and Child–Pugh scores (P< 0.001) compared with
patients with no muscular abnormalities (Table 1).
Lastly, patients with myosteatosis were older (P = 0.02), had
lower weight (P = 0.02), and lower frequency of overweight–
obesity (P< 0.001), lower L3 SMI (P< 0.001), muscle attenua-
tion (P< 0.001), and albumin (P = 0.03), and higher creatinine
(P = 0.001), INR (P< 0.001), and higher MELD (P = 0.001) and
Child–Pugh scores (P< 0.001) compared with patients with
no muscular abnormalities (Table 1). Otherwise, there were
no significant differences in clinical and biochemical features
among patients with sarcopenia, sarcopenic obesity and
myosteatosis and patients without muscular abnormalities
as shown in Table 1.
Survival in patients with sarcopenia, sarcopenic
obesity and myosteatosis
During mean follow-up of 21± 1months (range 1–164months),
248 patients received a liver transplant (37%), 259 died (38%)
and 171 (25%) were alive.
Patients with sarcopenia (22 ± 3 vs. 95 ± 22months,
P< 0.001), sarcopenic obesity (22 ± 3 vs. 95 ± 22months,
P< 0.001), and myosteatosis (28 ± 5 vs. 95 ± 22months,
P< 0.001) had worse median survival than patients without
muscular abnormalities.
Six-month probability of survival was 72%, 69% and 76% in
patients with sarcopenia, sarcopenic obesity and myosteatosis,
respectively, compared with 91% in patients without muscular
Figure 1 Venn diagram illustrating the association between sarcopenia,
myosteatosis and obesity.
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abnormalities. The 1-year probability of survival was 62%, 59%,
68% and 85% in the same groups, respectively (Figure 3).
Moreover, patients with either sarcopenia, sarcopenic obe-
sity and/or myosteatosis had significantly worse survival than
patients with none of these findings (29 ± 4 vs. 95
± 22months, P< 0.001), and patients who had both,
sarcopenic obesity and myosteatosis had the worse median
survival (19 ± 4 vs. 95 ± 22months, P< 0.001).
Finally, cirrhotic patients with sarcopenia without obesity had
worse median survival than non-sarcopenic patients (22±4 vs.
95 ±16months, P< 0.001), and patients withmyosteatosis with-
out sarcopenia had worse median survival than patients without
myosteatosis (41±13 vs. 95±22months, P=0.03), whereas pa-
tients with overweight–obesity had similar survival than patients
with normal BMI (41±14 vs. 38 ±6months, P=0.8).
Sub-analysis in patients without hepatocellular
carcinoma
In the sub-analysis excluding the 291 patients with concomi-
tant HCC (n = 387), patients with sarcopenia (21 ± 3 vs. 82
± 27months, P< 0.001), sarcopenic obesity (21 ± 2 vs. 82
± 27months, P< 0.001), and myosteatosis (28 ± 7 vs. 82
± 27months, P = 0.02) had worse median survival than pa-
tients without muscular abnormalities.
Features associated with mortality
By Cox regression analysis, biochemical values, including
levels of INR (P< 0.001), albumin (P = 0.002), bilirubin
(P< 0.001), sodium (P = 0.01), the L3 SMI (P< 0.001), and
muscle attenuation (P< 0.001), presence of sarcopenia
(P< 0.001), sarcopenic obesity (P< 0.001), myosteatosis
(P = 0.003), and MELD (P< 0.001) and Child–Pugh score
(P< 0.001) were significantly associated with mortality in pa-
tients with cirrhosis (Table 2).
In the multivariate Cox analysis including the presence of
age, sodium, sarcopenia, myosteatosis, MELD, Child–Pugh
and NASH cirrhosis (excluding INR, albumin and bilirubin
to avoid colinearity, as they are included in either Child–
Pugh or MELD scores. Also sarcopenic obesity was not in-
cluded, as this is a subset of sarcopenia), only sarcopenia
[hazard ratio (HR) 2.00, P< 0.001], myosteatosis (HR 1.42,
P = 0.04), MELD (HR 1.04, P = 0.001) and NASH cirrhosis
(HR 0.60, P = 0.01) were independently associated with
mortality (Table 3).
Figure 2 Computed tomography images used for the muscularity assessment of patients with cirrhosis. Comparison of two cirrhotic patients with se-
vere obesity. (A) Male patient at the left had sarcopenic obesity (BMI 47 kg/m2, L3 SMI 51 cm2/m2), whereas a female patient at the right (B) had no
sarcopenia (BMI 42 kg/m2, L3 SMI 49 cm2/m2). Computed tomography images used for the muscle attenuation assessment of patients with cirrhosis
and comparison of two cirrhotic patients with similar BMI (28 kg/m
2
). (C) Patient at the left had low mean muscle attenuation (21 HU), whereas the
patient at the right (D) had normal mean muscle attenuation (40 HU).
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Causes of death in patients with sarcopenia,
sarcopenic obesity and myosteatosis
Of the 259 patients who died, 54 patients (21%) died from liver
failure, 69 (27%) died from sepsis, 43 (17%) died from HCC pro-
gression, 18 (7%) died from hepatorenal syndrome, 9 patients
(3%) died from variceal bleeding and 66 patients (25%) died
from other reasons (cardiac arrest, cerebrovascular events,
trauma, extrahepatic malignancies, unknown and others).
In the analysis of the 259 who died, the frequency of
sepsis-related death was significantly higher in cirrhotic pa-
tients with sarcopenia [49 (36%) vs. 20 (16%), P< 0.001;
Figure 4(A)], myosteatosis [47 (32%) vs. 22 (19%), P = 0.02;
Figure 4(B)], and sarcopenic obesity [24 (36%) vs. 45 (23%),
P = 0.05; Figure 4(C)] than patients without muscular abnor-
malities. Finally, patients without myosteatosis had higher
frequency of liver failure-related death [31 (27%) vs. 23
(16%), P = 0.03; Figure 4(B)] than patients with myosteatosis.
Otherwise, there were no significant differences in the fre-
quency of death related to liver failure, HCC progression,
hepatorenal syndrome, variceal bleeding and other
aetiologies among patients with and without muscular abnor-
malities [Figure 4(A–C)].
Outcomes after liver transplantation in patients
with sarcopenia, sarcopenic obesity and
myosteatosis
Two-hundred and forty-eight patients had a liver transplant,
and of them 112 (45%) had sarcopenia, 42 (17%) had
sarcopenic obesity and 116 (47%) had myosteatosis. Median
survival after liver transplant was not different among
sarcopenic and non-sarcopenic patients (117 ± 17 vs. 146
± 19months, P = 0.4), patients with and without sarcopenic
obesity (114 ± 8 vs. 132 ± 112months, P = 0.1), nor patients
with and without myosteatosis (117 ± 19 vs. 142 ± 17months,
P = 0.1).
Sarcopenic patients had longer hospital stay (40 ± 4 vs. 25
± 3 days, P = 0.001) and intensive care unit stay after liver
transplantation (12 ± 2 vs. 6 ± 1 days, P = 0.005) than non-
sarcopenic patients. Patients with myosteatosis had longer










Age (years) 56±1***** 57±1 58±1***** 58±1*****
Gender (male:female) 142:68*,*** 232:59* 113:22*** 218:135
Weight (kg) 83±1**,***** 77± 1** 90±2** 79±1*****
Height (cm) 169±0.5** 174± 0.5** 175±0.5** 170±0.5
BMI (kg/m2) 29±0.5**,******* 25±0.5** 30±0.5 27±0.5*******
Obesity–overweight 169 (81)** 135 (46)** — 192 (54)**
Diabetes 27 (13) 43 (15) 20 (15) 55 (16)
L3 SMI (cm2/m2) 57±1** 43±0.5** 45±1** 48± 1**
Muscle attenuation (HU) 42± 0.5** 33±0.5** 32±1** 29±0.5**
Sarcopenia — — — 176 (50)
Myosteatosis — 176 (60) 77 (57) —
Sarcopenic Obesity — 135 (46) — 77 (22)
Creatinine (nl, 50–115 μmol/L) 79±3***,** 105±7*** 114±11** 99± 5***
INR (nl, 0.8–1.2) 1.3± 0.3****,*****,** 1.5± 0.4**** 1.5± 0.2***** 1.5± 0.3**
Albumin (nl, 35–50 g/L) 33± 1******** 33±0.5 32±1 32±1********
Bilirubin (nl, <20 μmol/L) 67±11***** 99±13 125±19***** 92±9
Sodium (nl 133–146 μmol/L) 136±1 135±0.5 135±1 135± 1
MELD 13± 1****,****** 15±1**** 16± 1****** 15± 1***
Child–Pugh (A/B/C) 43/135/31** 37/149/106** 12/64/59** 43/180/130**
Child–Pugh (points) 8± 0.2** 9±0.2** 10±0.2** 10±0.2**
Aetiology of Cirrhosis
Alcohol 38 (18) 85 (29) 41 (30) 86 (24)
HCV 93 (44.5) 106 (36.5) 51 (38) 131 (37)
AILDa 15 (7) 23 (8) 8 (6) 30 (9)
HBV 18 (9) 18 (6) 8 (6) 14 (4)
NASH-Cryptogenic 44 (21) 59 (20) 26 (19) 88 (25)
Othersb 1 (0.5) 1 (0.5) 1 (1) 4 (1)
Concomitant HCC 97 (46) 115 (39) 57 (42) 145 (41)
AILD, autoimmune liver disease; BMI, body mass index; L3 SMI, lumbar third skeletal muscle index; CI, confidence interval; HBV, hepatitis B
virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HU, Hounsfield units; INR, international normalized ratio; MELD, model for
end stage liver disease; NASH, non-alcoholic steatohepatitis; nl, normal.
aInclude autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.
bInclude alpha-1-antitrypsin deficiency, hemochromatosis and Wilson disease.
Numbers in parentheses are percentages.
Significantly different from each other at the level of *P=0.003; **P< 0.001; ***P=0.001; ****P=0.006; *****P=0.02; ******P=
0.009; *******P=0.002; ********P=0.03.
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Figure 3 Kaplan–Meier curve indicating the survival of patients with sarcopenia (—), sarcopenic obesity (--), myosteatosis (--) and without muscular
abnormalities (—). The 6-month probability of survival was 72%, 69%, 76% and 91%, respectively (P< 0.001, log-rank test). The 1-year probability of
survival was 62%, 59%, 68%, and 85% in these same groups, respectively.
Table 2 Features associated with mortality by univariate Cox analysis in patients with cirrhosis
Features associated with mortality by univariate analysis Death (n=259) Alive (n=419) HR 95% CI P-value
Age (years) 56± 1 57± 1 0.99 0.97–1.01 0.07
Gender (male:female) 172:87 285:134 1.05 0.81–1.36 0.7
Weight (kg) 80± 1 79± 1 1.00 0.99–1.01 0.4
BMI (kg/m2) 28± 1 27± 1 1.00 0.98–1.02 0.9
Obesity-overweight 165 (64) 254 (61) 1.04 0.80–1.34 0.8
Diabetes 20 (8) 59 (14) 0.69 0.45–1.10 0.1
Creatinine (nl, 50–115 μmol/L) 96± 5 91± 5 1.00 0.99–1.00 0.9
INR (nl, 0.8–1.2) 1.5± 0.4 1.4±0.2 1.97 1.56–2.48 <0.001
Albumin (nl, 35–50 g/L) 32± 1 33± 1 0.96 0.94–0.99 0.002
Bilirubin (nl, <20 μmol/L) 99± 12 80± 9 1.02 1.01–1.03 <0.001
Sodium (nl, 133–146 μmol/L) 135±1 136±1 0.96 0.93–0.99 0.01
L3 SMI (cm2/m2) 49± 1 51± 1 0.98 0.97–0.99 0.001
-
Men
52± 1 54±1 0.97 0.95–0.98 <0.001
-
Women
52± 1 54±1 0.98 0.96–1.01 0.3
Muscle attenuation (HU) 34± 1 36±1 0.96 0.95–0.98 <0.001
Sarcopenia 135 (52) 157 (38) 1.98 1.55–2.53 <0.001
Sarcopenic obesity 66 (26) 69 (17) 1.72 1.30–2.28 <0.001
Myosteatosis 145 (56) 208 (50) 1.45 1.13–1.85 0.003
MELD Score 15± 1 14±1 1.05 1.03–1.07 <0.001
Child–Pugh (A/B/C) 27/161/71 78/215/126 1.43 1.17–1.74 <0.001
Child–Pugh (points) 9± 0.2 9±0.2 1.07 1.01–1.14 0.02
Alcohol cirrhosis 69 (27) 84 (20) 1.15 0.87–1.52 0.3
HCV cirrhosis 99 (38) 169 (40) 1.16 0.91–1.50 0.2
AILDa 16 (6) 39 (9) 0.74 0.44–1.22 0.2
HBV cirrhosis 16 (6) 27 (6) 1.17 0.71–1.94 0.5
NASH-cryptogenic cirrhosis 55 (21) 98 (23) 0.72 0.53–0.97 0.03
Concomitant HCC 107 (41) 184 (44) 0.89 0.69–1.15 0.4
AILD, autoimmune liver disease; BMI, body mass index; CI, confidence interval; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV,
hepatitis C virus; HR, hazard ratio; INR, international normalized ratio; MELD, model for end stage liver disease; NASH, non-alcoholic
steatohepatitis; nl, normal.
aInclude autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.
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intensive care unit stay (11 ± 2 vs. 6 ± 1 days, P = 0.02) than pa-
tients without myosteatosis, but no significant differences in
hospital stay (36 ± 3 vs. 28 ± 3 days, P = 0.09), and patients with
sarcopenic obesity had no differences in hospital (35 ± 6 vs. 31
± 2 days, P = 0.6) and intensive care unit stay (8 ± 2 vs. 8
± 1 days, P = 0.9) than patients without sarcopenic obesity.
Finally, bacterial infections within the first 90 days after
liver transplantation were more frequent for sarcopenic than
non-sarcopenic patients (26 vs. 15%, P = 0.04), but no signifi-
cant differences in bacterial infections were observed be-
tween patients with sarcopenic obesity (26 vs. 19%, P = 0.2)
and myosteatosis (20 vs. 20%, P = 0.6), compared with pa-
tients without these muscular abnormalities.
Discussion
Our study indicates that skeletal muscle abnormalities are
frequently present in patients with cirrhosis, with sarcopenia
being present in almost half of the patients; twenty percent
of them have sarcopenic obesity and fatty infiltration of skel-
etal muscle or myosteatosis being present in more than half
of cirrhotic patients.
Patients with cirrhosis and sarcopenia, sarcopenic obesity
and myosteatosis tend to be older, more frequently men
and have worse liver function assessed by MELD or Child–
Pugh scores compared with patients with no muscular abnor-
malities (Table 1).
Importantly, the presence of sarcopenia, sarcopenic obe-
sity and myosteatosis were associated with worse survival
compared with cirrhotic patients with no muscular abnormal-
ities. In fact, our study indicates that having sarcopenia and
myosteatosis increase the risk of mortality by 1.5- to twofold
compared with patients who do not have any of these mus-
cular abnormalities.
The risk of mortality associated with the presence of mus-
cular abnormalities (sarcopenia and myosteatosis) in cirrhotic
patients seems to be related to a higher frequency of sepsis-
related death (Figure 1). These findings are similar to a recent
study that found correlation between protein malnutrition
and sepsis in a cohort of hospitalized cirrhotic patients,34
and this might explain why conventional scores that reflect
mainly liver function, such as MELD and Child–Pugh, do not
detect mortality risks associated with skeletal muscle
abnormalities.10
Muscle wasting and fatty muscle infiltration in cirrhotic pa-
tients are part of the frailty complex present in these pa-
tients, characterized as decreased reserve and resistance to
stressors, resulting from cumulative declines across multiple
physiologic systems and predisposition to poor outcomes.20
Therefore, muscularity assessment including the L3 SMI and
muscle attenuation index are objective and reproducible,
and their assessment is not biased by overweight–obesity
and fluid overload status that frequently is present in pa-
tients with decompensated cirrhosis. Moreover, skeletal mus-
cle abnormalities in patients with cirrhosis seem to reflect a
chronic detriment in the general physical condition, rather
than acute severity of the liver disease.
The pathogenesis of sarcopenia and myosteatosis in cir-
rhotic patients is not completely elucidated, but it seems to
be the result of a complex interaction involving dysregulation
of fatty acid oxidation and ketogenesis, gluconeogenesis from
amino acids, glycogenolysis and selective utilization of aro-
matic amino acids in the liver and branched chain amino
acids in the skeletal muscle.35,36 Proinflammatory cytokines,
tumour necrosis factor-α, interleukin-6 and C-reactive protein
have been shown to mediate skeletal muscle catabolism,
leading to sarcopenia.37 Also, there is impairment of skeletal
muscle protein synthesis in portosystemic shunting because
of an increased expression of myostatin, a member of the
transforming growth factor beta superfamily,38,39 and au-
tophagy in skeletal muscle mediated by hyperammonemia.40
One limitation of our study is that we used a definition
of sarcopenia based on cut-point values validated in a dif-
ferent population,32 as predefined values for sarcopenia in
patients with cirrhosis have not been validated; however,
the values we used were derived from optimum stratifica-
tion of the L3 SMI, finding the most significant P-values
to define gender-specific cut-points associated with mortal-
ity in patients with malignancy and obesity.32 We have
Table 3 Features associated with mortality by multivariate Cox analysis in patients with cirrhosis
Features associated with mortality by multivariate analysis Death (n=259) Alive (n=419) HR 95% CI P-value
Age (years) 56± 1 57±1 0.99 0.97–1.02 0.8
Sodium (nl, 133–146 μmol/L) 135±1 136±1 0.97 0.93–1.01 0.1
Sarcopenia 135 (52) 157 (38) 2.00 1.44–2.77 <0.001
Myosteatosis 145 (56) 208 (50) 1.42 1.02–1.99 0.04
MELD score 15± 1 14±1 1.04 1.02–1.07 0.001
Child–Pugh (points) 9± 0.2 9±0.2 0.92 0.85–1.01 0.07
NASH-cryptogenic cirrhosis 55 (21) 98 (23) 0.60 0.40–0.89 0.01
CI, confidence interval; HR, hazard ratio; MELD, model for end stage liver disease; NASH, non-alcoholic steatohepatitis; nl, normal.
Numbers in parentheses are percentages.
Variables included in the multivariate analysis were age, sodium, sarcopenia, myosteatosis, MELD, Child–Pugh, and NASH cirrhosis. INR,
bilirubin and albumin were not included to avoid colinearity, as they are included in either Child–Pugh or MELD scores. Also sarcopenic
obesity was not included, as this is a subset of sarcopenia.
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already demonstrated that these values are useful to distin-
guish cirrhotic patients with sarcopenia and higher risk of
mortality,10 and cut-point values are very similar to a pre-
liminary experience in patients with cirrhosis.41 Other po-
tential limitation is that our cohort of cirrhotic patients
was mainly composed of either patients with advanced
liver disease or with HCC, so our results may not reflect
the broader population of cirrhosis. The prevalence of mus-
cular abnormalities may be lower in a population-based co-
hort of cirrhotics.
In summary, despite the fact that skeletal muscle abnor-
malities, such as sarcopenia and myosteatosis, are not in-
cluded in the conventional scores for prognosis in cirrhotic
patients, such as the MELD or Child–Pugh scores, its presence
should alert clinicians to the same extent as other complica-
tions do, such as ascites, hepatic encephalopathy or variceal
bleeding.14,13
As sarcopenia and myosteatosis are frequent complica-
tions in cirrhotic patients and are predictive of longer hospital
stays and a higher risk of perioperative bacterial infections
Figure 4 Percentage of mortality related to liver failure, sepsis, hepatocellular carcinoma progression, variceal bleeding, hepatorenal syndrome
and others in cirrhotic patients with (A) sarcopenia, (B) myosteatosis and (C) sarcopenic obesity. GI, gastrointestinal; HCC, hepatocellular carcinoma;
HRS, hepatorenal syndrome.
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after liver transplantation, but are not associated with in-
creased post-liver transplant mortality,42 modification of cur-
rent allocation systems to include muscle abnormalities may
decrease mortality in patients with cirrhosis awaiting for liver
transplantation.
Cirrhotic patients are frequently overweight or obese, and
body composition assessments with CT images help to dis-
close otherwise occult sarcopenia and/or myosteatosis. Cir-
rhotic patients with sarcopenia and myosteatosis have a
worse prognosis compared with patients with no skeletal
muscular abnormalities, regardless of overall body weight
or BMI, mainly to higher risk of sepsis-related mortality.
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